DL‐3‐n‐butylphthalide accelerates improvement of early‐onset post‐stroke cognitive impairment

Abstract

Background: Post‐stroke cognitive impairment (PSCI) affects nearly 1/3 of stroke patients, which results in high mortality rates, high disability rates and high social and family burdens. Most PSCI occur in the early stages of stroke, known as early‐onset PSCI, for which there are no specific treatment currently.